Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. - Wikidata - wikimedia - TriplyDB

Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.

Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.

http://www.wikidata.org/entity/Q35233808

about

The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients Diet therapy for inflammatory bowel diseases: The established and the new The gut microbiota and host health: a new clinical frontier The Intestinal Microbiota in Inflammatory Bowel Disease The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis MyD88 mediates the protective effects of probiotics against the arteriolar thrombosis and leukocyte recruitment associated with experimental colitis.Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease Comparison of microbiological, histological, and immunomodulatory parameters in response to treatment with either combination therapy with prednisone and metronidazole or probiotic VSL#3 strains in dogs with idiopathic inflammatory bowel disease Chemical characterization and immunomodulatory properties of polysaccharides isolated from probiotic Lactobacillus casei LOCK 0919 Probiotic Mix VSL#3 Is Effective Adjunctive Therapy for Mild to Moderately Active Ulcerative Colitis Diet, gut microbes, and the pathogenesis of inflammatory bowel diseases.An update on the use and investigation of probiotics in health and disease.Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease Potential role of nutraceutical compounds in inflammatory bowel disease The Emerging Therapeutic Role of Medical Foods for Gastrointestinal Disorders.Gut microbiota, probiotics, and human health Fecal Microbiota Transplantation: From Clostridium difficile to Inflammatory Bowel Disease.Amelioration of colitis in mouse model by exploring antioxidative potentials of an indigenous probiotic strain of Lactobacillus fermentum Lf1.The Probiotic Mixture VSL#3 Alters the Morphology and Secretion Profile of Both Polarized and Unpolarized Human Macrophages in a Polarization-Dependent Manner.Investigation of the impact of feeding Lactobacillus plantarum CRL 1815 encapsulated in microbially derived polymers on the rat faecal microbiota.Oats and bowel disease: a systematic literature review.Enteric microbiota leads to new therapeutic strategies for ulcerative colitis.Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients.Current and emerging drugs for the treatment of inflammatory bowel disease.Alteration of the intestinal microbiome: fecal microbiota transplant and probiotics for Clostridium difficile and beyond.The effect of probiotics and gut microbiota on Th17 cells.Probiotic actions on diseases: implications for therapeutic treatments.Probiotics, prebiotics and the gastrointestinal tract in health and disease.Probiotics, nuclear receptor signaling, and anti-inflammatory pathways.Relationship between gut microbiota and development of T cell associated disease.Gut microbiota, immunity, and disease: a complex relationship.Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation?Emerging science of the human microbiome.Gut microbiota and inflammatory bowel disease: the role of antibiotics in disease management.Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease.The gut microbiota and inflammatory bowel disease.Pretreatment with the probiotic VSL#3 delays transition from inflammation to dysplasia in a rat model of colitis-associated cancer.

P2860

Q26745700-4337E84A-5BD2-4939-98D5-8BF168B59156 Q26750985-63BD9B53-41E0-4696-AD42-901C60AC3724 Q26768564-7A34A0AE-7419-4110-9ABA-3184E1503C17 Q26785649-65AAEBE5-2B44-4B3C-B7BD-8BAB2AA91FE1 Q26795705-5C288E34-F642-4B5C-B558-0422443E0C12 Q27001546-AA010D9A-84CC-47DA-8DB2-1D74B832ED87 Q27001712-6FCC46A7-135B-44CC-925B-E30C200AC51D Q27314871-EBDDFC8B-58A2-4CD6-83D5-8BFDA9CDCD64 Q28072437-852FDAC7-9AD8-4884-AECC-ADFC0D89509D Q28254207-9C50E43B-AF4E-46CB-8AEF-2999C10B81F1 Q28537737-C91757F1-69BA-4E58-80F5-19631AFC4B78 Q28828166-51C6DAEA-4873-4F3D-B4D5-1162ABCAB879 Q29037475-D434FDB8-35EE-4DDA-AB62-6B6D45F86E4F Q30249313-7D269D74-7571-479F-ADED-9EE246F3890F Q30407565-D88E63DE-03D8-4ED9-89CC-8EEAE3D09EC0 Q30570535-F5E3A962-18D1-4A63-A9F2-B0BDAE3710BE Q33572633-4FFA22E4-B042-4118-8378-8C39F778F584 Q33595797-0BE31ECC-B1B5-4B25-A2A2-AA79FB60BF2E Q33666412-A5C9F020-EC0F-455D-B54D-1EE420D2A333 Q33717111-77E37D5C-F5C0-4207-BD9C-AF6E2D6A7529 Q33908943-E9211ABD-6305-4D48-9251-FEDBE1AA22AF Q34092270-2EB77EBF-2DF8-4B1C-9D56-32C72B9F28C7 Q34276096-845DF6C0-4DC8-4E6D-90E0-8E7E19BEE43B Q34440935-72886644-59F1-4A9A-A55E-28126F484843 Q34499080-07877D34-0903-4DAA-BB24-7E02BAB13176 Q34637606-C470A11D-C6AA-48DB-81A0-3BC60AF180FB Q34883210-D6C2C4D4-297C-4CFB-AB95-A3F95593557E Q35000008-DB106A4B-966E-4C1D-B2AF-756EB6546749 Q35008169-1E236A0C-570D-4BF2-BC02-EBC8A3D1BB37 Q35096915-C9262446-91F2-44B0-838E-62DD4A5C4F1E Q35122167-B5EF72EB-075C-4AC9-8750-EEF12F118F08 Q35131051-317F3064-A563-4D9D-9BEF-B0E5E1C30C13 Q35134829-DEC6FCFF-A269-41E1-B725-6B74DB2B9E68 Q35195785-7140D0AB-F829-4A8E-B7F5-40F913300919 Q35195891-9266239F-6971-4381-9E93-CBAD23B702D5 Q35205214-7B58CBF9-3841-4F2E-8DBF-3035D732A3F4 Q35228714-17833BDF-73CD-4105-B47F-88192BF800F5 Q35245299-82C112B5-FD96-49A2-9021-50DAD0B2DA09 Q35446516-260CC900-7F02-4B52-BEBB-7D6563599B9A Q35601294-2C390628-E5BD-4326-87A9-6E6AE5370E43

P2860

Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.

http://www.wikidata.org/entity/Q35233808

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Treatment of relapsing mild-to ...... zed, placebo-controlled study.

@ast

Treatment of relapsing mild-to ...... zed, placebo-controlled study.

@en

type

label

Treatment of relapsing mild-to ...... zed, placebo-controlled study.

@ast

Treatment of relapsing mild-to ...... zed, placebo-controlled study.

@en

prefLabel

Treatment of relapsing mild-to ...... zed, placebo-controlled study.

@ast

Treatment of relapsing mild-to ...... zed, placebo-controlled study.

@en

P1433

Q35233808-5865740C-4401-49EE-A49E-223EAB68D74C

P1476

Q35233808-21219C68-9A7A-426F-8B54-04837A8D2F56

P2093

Q35233808-15E13479-61B8-4A12-8EF0-64DD41735477

Q35233808-19D16D7B-5790-42EB-9070-0FA40AFF86FC

Q35233808-2048FD9C-EA7F-44A7-89B0-7FC13EBCE142

Q35233808-45E2387F-E0AE-4804-8900-25AC53902B8E

Q35233808-4873B493-02E1-42A0-9DED-DC309C889BE6

Q35233808-5DAF8869-5D6E-4B8F-9F45-02F36A812525

Q35233808-654C400A-8FF5-47FE-86A2-3A4C39411BFA

Q35233808-6C32B0F6-0413-4FA6-A5BF-63FD9DABAFF0

Q35233808-6E909F27-184E-446E-8C45-EDC265DFB3A5

Q35233808-836D14A7-A1A7-4101-B46A-B5C57685F53C

P2860

Q35233808-0A5352A7-57B1-4C98-9042-EA8AE782E151

Q35233808-18B4260A-99C0-4305-9F3B-5D1006C481F2

Q35233808-18C5058F-4776-4365-85C5-A0619B7ECA00

Q35233808-1AC18553-B705-444B-A398-C1867DBCF697

Q35233808-1CFC2F3C-2A03-417E-B90E-46F8CED5AC8A

Q35233808-203EE87F-6AE0-4ACE-BC56-10BFB3EC166E

Q35233808-2324430F-41BA-48DE-A51E-594062F8F137

Q35233808-241024CC-820A-4156-B7E2-707FCB2F8D75

Q35233808-2646D8B9-B380-4FE0-9FE1-3CE4C6A43A8F

Q35233808-31FC8FCE-9376-4846-8BF4-13C35FDF234F

P304

Q35233808-0530A444-15B8-4D4A-B2B8-66DAEE0E9774

P31

Q35233808-068F7D54-41BB-4E6F-9CCD-9193773F082C

P356

Q35233808-6BD2F35C-2844-465A-99BD-C873DB1BE840

P407

Q35233808-AB2BB67B-E81F-4608-AD35-55F16505D513

P433

Q35233808-F446B230-45FF-42F1-ACD5-745FB1E14D9F

P478

Q35233808-EDEA7A67-D5E7-4629-B6FC-59AB4296D560

P50

Q35233808-033088C8-F8BF-40AC-B734-489C08F5B0F0

Q35233808-1BF373C0-C183-44C2-AE71-18CED35F434C

Q35233808-456F817A-92E9-45D2-8669-F80CB7D1AE72

Q35233808-FEDACCCE-DF43-4C9B-BCBB-71195BE09FCD

P577

Q35233808-98A4740C-8C26-48C3-A45F-8C061A4EA4AE

P5875

Q35233808-021B64BA-E7E5-4F9A-ADAF-B9C902B63D8E

P698

Q35233808-0B2E4DB0-0D55-44F5-B6DC-117077FBC5C2

P921

Q35233808-13482132-B232-4044-9EC1-4A14D78CAA64

Q35233808-404EFFBE-A993-470A-A416-C30B198A3785

P932

Q35233808-D87F2ACB-0D13-4AFD-866F-F213DDB05645

P356

P1433

The American Journal of Gastroenterology

P1476

Treatment of relapsing mild-to ...... ized, placebo-controlled study

@en

P2093

Andrea Giglio

http://www.w3.org/2001/XMLSchema#string

Antonio Gasbarrini

http://www.w3.org/2001/XMLSchema#string

Antonio Tursi

http://www.w3.org/2001/XMLSchema#string

Emilio Di Giulio

http://www.w3.org/2001/XMLSchema#string

Giacomo Forti

http://www.w3.org/2001/XMLSchema#string

Gian Marco Giorgetti

http://www.w3.org/2001/XMLSchema#string

Giovanni Brandimarte

http://www.w3.org/2001/XMLSchema#string

Ladislava Sebkova

http://www.w3.org/2001/XMLSchema#string

Maria Antonietta Pistoia

http://www.w3.org/2001/XMLSchema#string

Maria Ester Modeo

http://www.w3.org/2001/XMLSchema#string

P2860

Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee

Probiotics for induction of remission in ulcerative colitis

Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

A pilot trial of Saccharomyces boulardii in ulcerative colitis

The gut microbiota shapes intestinal immune responses during health and disease

A microbial symbiosis factor prevents intestinal inflammatory disease

Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.

European evidence-based Consensus on the management of ulcerative colitis: Current management.

Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.

P304

2218-2227

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/AJG.2010.218

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

Tiziana Larussa

Francesco Luzza

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44643996

http://www.w3.org/2001/XMLSchema#string

P698

20517305

http://www.w3.org/2001/XMLSchema#string

P921

P932

3180711

http://www.w3.org/2001/XMLSchema#string